Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Liver Int. 2016 Jan 30;36(8):1176–1186. doi: 10.1111/liv.13055

Fig. 5. Loss of AKT2 inhibits liver tumor formation in PIK3CA H1047R/c-Met and PIK3CA E545K/c-Met mice.

Fig. 5

Gross images (upper panels) and hematoxylin and eosin (H&E) staining (middle and lower panels) of livers from AKT2 wild-type (AKT2+/+) or AKT2 knockout (AKT2−/−) mice injected with PIK3CA H1047R (HR) or PIK3CA E545K (EK) and c-Met (Met) constructs. Of note, hepatocarcinogenesis driven by the co-expression of PIK3CA mutants and c-Met is completely impaired in AKT2−/− mice. Magnification: 100X in middle panels; 200X in lower panels.